CIHealthcare · Healthcare PlansThe 24 Wall Street analysts covering The Cigna Group hold a median 12-month price target of $340 — +20.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores The Cigna Group on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.
Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own The Cigna Group — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on CI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +20.5% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 July 2026 | Barclays | Maintains | Equal-Weight | $304 → $310 |
| 31 July 2026 | Guggenheim | Maintains | Buy | $338 → $361 |
| 31 July 2026 | Wells Fargo | Maintains | Equal-Weight | $305 → $307 |
| 9 July 2026 | Bernstein | Maintains | Outperform | $371 → $381 |
| 8 June 2026 | Mizuho | Maintains | Outperform | — |
| 26 May 2026 | Barclays | Downgrade | Equal-Weight | — |
| 22 May 2026 | UBS | Maintains | Buy | — |
| 20 May 2026 | Deutsche Bank | Downgrade | Hold | — |
| 20 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 5 May 2026 | Bernstein | Maintains | Outperform | — |
| 4 May 2026 | Guggenheim | Maintains | Buy | — |
| 1 May 2026 | Barclays | Maintains | Overweight | — |
| 1 May 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 1 May 2026 | RBC Capital | Maintains | Outperform | — |
| 1 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 20 Apr 2026 | Jefferies | Maintains | Buy | — |
| 12 Mar 2026 | Bernstein | Upgrade | Outperform | — |
| 3 Mar 2026 | Piper Sandler | Reiterates | Overweight | — |
| 17 Feb 2026 | Truist Securities | Reiterates | Buy | — |
| 9 Feb 2026 | TD Cowen | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 56% of US stocks
Cheaper than 90% of US stocks
Cheaper than 49% of US stocks
Cheaper than 47% of US stocks
Higher than 46% of US stocks
Higher than 48% of US stocks
Higher than 10% of US stocks
Higher than 55% of US stocks
Higher than 53% of US stocks
Higher than 77% of US stocks
Higher than 74% of US stocks
Higher than 49% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CI appears on the weeks it earns a place.
Seeking Alpha reaffirmed a Buy rating on Cigna, noting its valuation remains deeply discounted despite steady earnings growth, raised 2026 adjusted EPS guidance to at least $30.45, and ongoing capital returns including buybacks and a $1.56 per share dividend.
Why it matters — CI watchers would note the raised EPS guidance and continued capital return program as signs of financial momentum and shareholder value focus.
Cigna Group raised its full-year 2026 adjusted earnings outlook after reporting second-quarter results that exceeded expectations in its Evernorth health services business and Cigna Healthcare insurance segment.
Why it matters — An upward earnings revision signals stronger-than-expected operational performance across both of Cigna's core business segments, which may influence investor confidence in the company's growth trajectory.
Cigna reported Q2 earnings and revenue that beat estimates, driven by strength in its Cigna Healthcare segment, and raised its 2026 EPS outlook despite higher pharmacy costs.
Why it matters — The earnings and revenue beat, along with an improved forward outlook, signals strong underlying performance in Cigna's core health insurance business.
Cigna reported second-quarter earnings results and its stock fell. The company expects lower growth in popular GLP-1 drug prescriptions.
Why it matters — GLP-1 drugs are a major cost driver for pharmacy benefits, so lower growth in their prescriptions could affect Cigna's financial outlook.
Zacks Investment Research reported on Cigna's Q2 2026 earnings, comparing the company's key metrics against Wall Street estimates and the prior year's actuals.
Why it matters — The analysis of how Cigna's key quarterly metrics stack up against estimates and the year-ago period helps investors gauge the company's operational performance beyond headline figures.
The 24 Wall Street analysts covering The Cigna Group have a median 12-month price target of $340, with estimates ranging from $290 to $400. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 24 analysts covering The Cigna Group, 20 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks The Cigna Group 53 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, The Cigna Group ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
No one can know that. What the data says: the median 12-month target from 24 analysts implies +20.5% from the last close, and Ticker Nerd's factor model ranks The Cigna Group 53 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering The Cigna Group publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $290 to $400 over the next 12 months.
The Cigna Group returned +9.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
The Cigna Group is a global health company that provides a broad range of health services and solutions to individuals, employers, health plans, and government organizations. Through its Evernorth Health Services segment, the company delivers pharmacy benefit management, home delivery and specialty pharmacy services, specialty drug distribution, and care delivery and management solutions that support cost-effective and clinically focused care.
The most recent item we track (Seeking Alpha, 31 July 2026): "Cigna's Valuation Gap Still Stands Out". Seeking Alpha reaffirmed a Buy rating on Cigna, noting its valuation remains deeply discounted despite steady earnings growth, raised 2026 adjusted EPS guidance to at least $30.45, and ongoing capital returns including buybacks and a $1.56 per share dividend.
The Cigna Group is a global health company that provides a broad range of health services and solutions to individuals, employers, health plans, and government organizations. Through its Evernorth Health Services segment, the company delivers pharmacy benefit management, home delivery and specialty pharmacy services, specialty drug distribution, and care delivery and management solutions that support cost-effective and clinically focused care. Its Cigna Healthcare segment offers comprehensive medical coverage and coordinated health solutions across U.S. commercial, government, and international markets, serving employers and other institutional clients as well as individuals. The Other Operations and Corporate segments encompass remaining business activities and centralized functions, including certain ongoing and exited businesses, corporate overhead, and shared services. Headquartered in Bloomfield, Connecticut, and founded in 1792, The Cigna Group plays a significant role in the managed health care and health services sector by integrating benefits, clinical programs, and pharmacy capabilities to support access to healthcare and coordinated patient care.
CEO Mr. Brian Case Evanko C.F.A. · 65,669 employees · United States · https://www.thecignagroup.com